skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines everolimusQuestion & answer

everolimus · Medicine question

How does binding to FKBP-12 enable everolimus to inhibit mTORC1?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Everolimus binds to the intracellular protein FKBP-12, forming a complex that inhibits mTOR complex-1 (mTORC1) activity.

Sources for this answer

Afinitor TabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 37Document updated 25 July 2022

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about everolimus

Can Afinitor (everolimus) tablets be chewed or crushed?For which patients with advanced breast cancer is Afinitor (everolimus) indicated?How does cannabidiol affect everolimus exposure?How long should breastfeeding be avoided during and after everolimus treatment?How much lactose does each Afinitor (everolimus) 10 mg tablet contain?How should Afinitor (everolimus) tablets be stored?

everolimus

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the everolimus guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX